How to Buy Adaptimmune Therapeutics Stock

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.

Adaptimmune Therapeutics stock last closed at $1.06, up 0% from the previous day, and has decreased 50.23% in one year. It has underperformed other stocks in the Biotechnology industry by 0.24 percentage points. Adaptimmune Therapeutics stock is currently +4.95% from its 52-week low of $1.01, and -60% from its 52-week high of $2.65.

As of Mar 29, 2023, there are 991.83M ADAP shares outstanding. The market capitalization of ADAP is $175.57M. In the last 24 hours, 355,219 ADAP shares were traded.

How to Buy Adaptimmune Therapeutics Stock

Not sure how to invest in Adaptimmune Therapeutics stock? Here's how.
  1. Decide where to buy Adaptimmune Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Adaptimmune Therapeutics stock.
  2. Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
  3. Fund your investment account: Choose your payment method and add your info.
  4. Research Adaptimmune Therapeutics stock: The Adaptimmune Therapeutics ticker symbol is ADAP. Is Adaptimmune Therapeutics stock a good investment? Should you buy shares of ADAP? How do ADAP's underlying business fundamentals look? Do top analysts think Adaptimmune Therapeutics is a good buy? Why has ADAP's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if ADAP is a good stock to buy).
  5. Make your ADAP trade: Decide if you will purchase ADAP shares at the current market price or use a limit order to buy ADAP shares at a specific price.
  6. Track your ADAP position: Create a watchlist to watch your new investment in Adaptimmune Therapeutics stock.

Step 1: Decide where to buy Adaptimmune Therapeutics stock

You need a brokerage account to access the NASDAQ market and buy ADAP stock.

A brokerage account is an investment account that allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.

Our favorite brokerage: eToro

Based on our research, eToro is the best brokerage. eToro gives you:

  • Invest in stocks with zero commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
  • Access to world markets: From Tech to Industrials, New York to Tokyo — you can fill your portfolio with stocks from the world's leading stock exchanges.
  • Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
  • Security: eToro is a regulated and licensed brokerage platform.
  • Buy other financial assets: Such as ETFs and cryptos.

Get $10 towards your purchase of shares by opening an account with eToro today.

Open eToro Account

Step 2: Open your brokerage account

Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in ADAP stock today.

How to Open a New Investment Account on eToro

  1. Click here to get started.
  2. Provide your personal info to open your new brokerage account.
  1. Submit your application by clicking the "Create Account" button.
Get started with eToro today

Step 3: Fund your investment account

Now that you've finished signing up on the best stock market app for beginners, you can securely and quickly fund your account:

Check out the walkthrough below to see the process of depositing funds into your new investment account.

Get started with eToro today

Step 4: Research Adaptimmune Therapeutics stock

After you have decided on the best place to buy Adaptimmune Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk and upside.

Adaptimmune Therapeutics Numbers

ADAP Price
1w %
1y %
5y %
Fore. Rev. Growth
Fore. Earn. Growth
Market Cap
Next Earnings
May 8, 2023
Next Dividend

Adaptimmune Therapeutics Fundamentals

WallStreetZen was designed to help everyday investors perform better fundamental analysis.

You can see all of the due diligence checks on ADAP's stock page.

Is ADAP stock overvalued?

Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ADAP's true value.

Using relative valuations ratios:

  • ADAP could be undervalued based on its P/B ratio of 2.14x, relative to Biotechnology industry P/B ratio of 4.92x

You can do more valuation analysis on ADAP's stock here.

How do ADAP Financials look?

Signs that ADAP is financially healthy:

  • There are more short-term assets than long-term liabilities on the ADAP balance sheet.
  • ADAP has cash burn of 171265000. It has sufficient cash and short-term investments to cover this for at least one year.
  • There are more short-term assets than short-term liabilities on the ADAP balance sheet.

Signs that ADAP is not financially healthy:

  • Total ADAP debt is higher than 5 years ago, relative to shareholder equity.
  • ADAP has $206.17M in cash and short term investments. This is not sufficient to cover its annual cash burn of $171.27M.
  • ADAP has a relatively high debt to equity ratio of 3.02.
  • ADAP profit margin has gone up by 19.62 percentage points in the past year, but the company is still unprofitable.

Is it a good time to buy Adaptimmune Therapeutics stock, according to Wall Street analysts?

Out of 5 Wall Street analysts who give recommendations on ADAP, the consensus analyst rating on ADAP is a Buy

Please note that analyst forecasts are not recommendations, nor are they investment advice.

Latest ADAP Analyst Recommendations

Tony Butler, a bottom 6% analyst from EF Hutton reiterates ADAP with a strong buy rating and maintains their ADAP price target from $10.00 to $10.00, on Mar 6, 2023.

Michael Schmidt, a top 15% analyst from Guggenheim upgrades ADAP to a strong buy rating and announces their ADAP price target of $5.00, on Jan 3, 2023.

Yanan Zhu, a bottom 2% analyst from Wells Fargo maintains ADAP with a hold rating and raises their ADAP price target from $1.50 to $3.00, on Nov 14, 2022.

Mara Goldstein, a bottom 38% analyst from Mizuho upgrades ADAP to a strong buy rating and announces their ADAP price target of $9.00, on Nov 9, 2022.

Nick Abbott, a bottom 24% analyst from Wells Fargo maintains ADAP with a hold rating and lowers their ADAP price target from $7.00 to $1.50, on Oct 4, 2022.

You can dig deeper into what analysts are forecasting on the Adaptimmune Therapeutics stock forecast page.

ADAP Momentum

MACD Signal
MACD Histogram
Stochastic %K
Stochastic %D
StochRSI %K
StochRSI %D

How are ADAP Revenues/Earnings doing?

Last year, ADAP revenue was $27.15M. Over the last five year, ADAP's revenue has gone up by -6.42% per year. This was slower than the Biotechnology industry average of 41.18%.

Dive into ADAP's earnings and revenue performance here.

Latest Insiders Trades at ADAP

Over the past year, executives and large shareholders at ADAP have sold more shares than they have bought.

Cintia Piccina, Chief Commercial Officer of ADAP, was the latest ADAP insider to sell. They sold $22,234.30 worth of ADAP shares on Jan 31, 2023.

Dig into more about who owns ADAP shares here.

Can I get consistent income from ADAP stock?

No, Adaptimmune Therapeutics doesn't provide an income stream by paying out dividends.

Get opinions from other investors

One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.

Click below to learn what other investors have to say.

Step 5: Make your ADAP trade

You have two primary types of orders:

  • Market order: A market order is an order to buy or sell a stock at the best available price.
    Market orders are mostly the easiest way to buy.
  • Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
    If you want to be sure you're buying or selling at an exact price limit, place a limit order.

Click the Open button and eToro will execute the order.

If you need additional assistance investing in stocks on eToro, watch the helpful video below:

Open eToro Account

Step 6: Track your ADAP position

Now that you own some shares in ADAP, you'll want to stay up-to-date on your stock purchase.

Create a watchlist to keep tabs on your ADAP stock.


How to Buy Stock in Adaptimmune Therapeutics

To summarize, here are the 6 steps you need to take to buy Adaptimmune Therapeutics stock right now:

  1. Decide where to buy Adaptimmune Therapeutics stock
  2. Open your brokerage account
  3. Fund your investment account
  4. Research Adaptimmune Therapeutics stock
  5. Make your ADAP trade
  6. Track your ADAP position

If you are looking for a brokerage, eToro is our favorite option.

Get Started with eToro Today

If you want to get notifications regarding your investment in Adaptimmune Therapeutics, click below.

$1.06+0.00 (+0%)
Updated Mar 29, 2023
Open eToro Account
$1.06+0.00 (+0%)
Updated Mar 29, 2023
Open eToro Account


How much does it cost to buy one Adaptimmune Therapeutics share?

As of Mar 29, 2023, it costs $1.06 to buy one share of Adaptimmune Therapeutics stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.53, you can buy 0.5 shares of ADAP.

Get Started with eToro Today

Is now a good time to buy Adaptimmune Therapeutics stock?

According to 5 Wall Street analysts who monitor Adaptimmune Therapeutics, their consensus recommendation is to buy Adaptimmune Therapeutics stock.

What is the best way to buy Adaptimmune Therapeutics stock?

One way to place an order for Adaptimmune Therapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.